54
Participants
Start Date
May 31, 2006
Primary Completion Date
March 31, 2009
Study Completion Date
March 31, 2009
AR Antagonist (BMS-641988)
Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
Memorial Sloan-Kettering Cancer Center, New York
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore
University Of Wisconsin Hospital And Clinics Laboratory, Madison
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY